Benzinga's Volume Movers

shares climbed 10.38 percent to $68.27. The volume of Teva shares traded was 1034 percent higher than normal. Teva announced its plans to buy

generic drugs unit for $40.5 billion in a cash and stock deal. Teva also reported that it has dropped its $40 billion cash and stock bid for

.

surged 5.12 percent to $315.38. The volume of Biogen shares traded 524 percent higher than normal. Bernstein analyst Geoffrey C. Porges upgraded the rating on Biogen from Market-Perform to Outperform, while reducing the price target from $436 to $385.

shares moved up 3.75 percent to $193.49. The volume of Perrigo traded was 478 percent higher than normal. Perrigo is expected to release Q2 results on August 5, 2015.

shares rose 6.06 percent to $326.89. The volume of Allergan shares traded was 437 percent higher than normal. Teva announced its plans to buy Allergan's generic drugs unit for $40.5 billion in a cash and stock deal.